Use of alprostadil, a stable prostaglandin E1 analogue, for the attenuation of rat skeletal muscle ischemia and reperfusion injury

Minerva Chirurgica

Volumn 64, Issue 6, 2009, Pages 559-564

  Antonio, L G M ^a   Evora, P R B ^a   Piccinato, C E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alprostadil; Rats; Reperfusion injury muscle, skeletal

Indexed keywords

PROSTAGLANDIN E1;

ANIMAL; ARTICLE; CONGENITAL MALFORMATION; MALE; RAT; REPERFUSION INJURY; SKELETAL MUSCLE; WISTAR RAT;

ALPROSTADIL; ANIMALS; MALE; MUSCLE, SKELETAL; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 77949766934     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rowlands TE, Gough MJ, Homer-Vanniasinkam. Do prostaglandin have a salutary role in skeletal muscle ischemia reperfusion injury? Eur J Vasc Endovasc Surg 1999;18:439-444
2. Thomson IA, Egginton S, Hudlicka O, Sims MH. Iloprost reduces leukocyte adhesion in skeletal muscle venules following ischemia in a rat model of femorodistal bypass. Eur J Vasc Surg 1994;8:335-341
3. Knight KR, Crabb DJMK, Niall M, Angus JA. Pharmacologic modification on blood flow in the rabitt microvasculature with prostacyclin and related drugs. Plast Reconstr Surg 1985;75:692-702.
4. 1 reduces ischemia-reperfusion injury by normalizing nitric oxide and superoxide release. Shock 2000;14:234-242
5. Bozkurt AK. Alpha-tocopherol (vit E) and iloprost attenuate reperfusion injury in skeletal muscle ischemiareperfusion injury. J Cardiovasc Surg (Torino) 2002;45:693-696
6. Perry MO, Fantini G. Ischemia: profile of an enemy. Reperfusion injury of skeletal muscle. J Vasc Surg 1987;6:231-234
7. Henry JR, Chiamori N, Golub OJ, Berkman S. Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase and lactic acid dehydrogenase. Am J Clin Pathol 1960;34:381-398
8. Keiding R, Horder, M, Gerhardt W. Recommended methods for determination of four enzymes in blood. Scand J Clin Lab Invest 1974;33:291-306.
9. Hassid, WZ; Abraham, S. Chemical procedures for analysis of polysaccharides. Meth Enzymol 1957;3:34-50.
10. Piccinato CE, Roselino JES, Massuda CA, Cherri J. Lack of chlorpromazine effect on skeletal muscle metabolism after ischemia and a short reperfusion period. Microsurgery 2004;24:194-199
11. Kearns SR, Daly AF, Sheehan E, Murray P, Kelly C, Bouchier-Hayes D. Oral vitamin C reduces the injury to skeletal muscle caused by compartmental syndrome. J Bone Joint Surg Br 2004;86:906-911
12. Koksal C, Bozkurt AK, Cangel U, Ustundag N, Konucog D, Musellim B et al. Attenuation of ischemia reperfusion injury by N-acetyl cysteine in a rat hind limb model. J Surg Res 2003;111:236-239
13. Oredsson S, Plate G, Ovarfordt P. Experimental evaluation of oxygen free radical scavengers in the prevention of reperfusion injury in skeletal muscle. Eur J Surg 1994;160:97-103.
14. Seyama A. The role of oxygen-derived free radicals and the effect of free radical scavengers on skeletal muscle ischemia - reperfusion injury. Surg Today 1993;23:1060-1067
15. Piccinato E, De Domenico JrAJ ordão Jr AA, Vannucchi H. Skeletal muscle ischemia and reperfusion increase lipid perxidation in rats. Acta Cir Bras 2004;19:578-581
16. Mc Cord, Roy RS. The pathophysiology of superoxide: roles in inflammation and ischemia. Can J Physiol Pharmacol 1982;60:1346-1352
17. 1 in severe peripheral vascular disease. Lancet 1975;7793:155-156
18. 1, iloprost, and nitroprusside in lung ischemia-reperfusion. Transplantation 2002;71:185-193
19. Katircioglu SF, Ulus AT, Gokce P, Surucu, S. Iloprost protects the spinal cord during aortic crossclamping in a canine model. J Cardiovasc Surg (Torino) 2000;41:89-93.
20. Rajagopal U, Friedman RM, Robinson JB Jr, Rohrich RJ. Iloprost enhances survival of axial-pattern skin flaps in a ischemia reperfusion model. Plast Reconstr Surg 1995;95:884-887
21. Dosluoglu HH, Aktan AO, Yegen C, Okboy N, Siiha Y. The cytoprotective effects of verapamil and iloprost (ZK 36374) on ischemia-reperfusion of kidney. Transpl Int 1993;6:138-142
22. Okboy N, Aktan AO, Yegen C, Dosluoglu HH, Sav A, Yalin R et al. The effect of iloprost and NDGA in ischemia-reperfusion injury in rat liver. Prostaglandins Leukot Essent Fatty Acids 1992;47:291-295
23. Cargnoni A, Condorelli E, Boraso A, Comini L, De Giuli F, Pasini E et al. Role timing of administration in the cardioprotective effect of iloprost, a stable prostacyclin mimetic. Eur J Pharmacol 1991;199:165-178
24. Blebea J, Cambria RA, De Fouw D, Feinberg RW, Robson RW, Duran WN. Iloprost attenuates the increased permeability in skeletal muscle after ischemia and reperfusion. J Vasc Surg 1990;12:657-666
25. Belkin M, Wright JG, Hobson II RW. Iloprost infusion decreases skeletal muscle ischemia-reperfusion injury. J Vasc Surg 1990;11:77-83.
26. Morrow JD, Roberts II J. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Hardman JG, Limbird L E , editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 669-685
27. Mohan C, Marini C, Gennaro M, Ascer E. The value and limitation of iloprost infusion in decreasing skeletal muscle necrosis. J Vasc Surg 1992;16:268-273
28. Tauber S, Menger MD, Lehr HA. Microvascular in vivo assessment of reperfusion injury: significance of prostaglandin El and 12 in postischemic "no-reflow" and "reflow-paradox". J Surg Res 2004;120:1-11.
29. Maulik M, Seth SD, Maulik SK, Manchanda SC. Effects of supplementation with iloprost on the cardioprotection by BW755C (a dual inhibitor of cyclooxygenase and lipoxygenase enzymes) in myocardial reperfusion injury. Pharmacol Res 1997;36:103-108
30. Klein HH, Pich S, Bohle RM, Schuff-Werner P. Failure of iloprost to protect the regionally ischemic, reperfused porcine heart. J Moll Cell Cardiol 1991;23:963-972
31. Perry MO. Compartment syndrome and reperfusion injury. Surg Clin N Am 1988;68:853-864